News

These results do not necessarily mean that gene silencing does not work when combined with a stabilizer, but show more research is needed.

A new Phase 4 trial will study the long-term effects of acoramidis on heart structure, function and amyloid burden in people with ATTR-CM.

Being aware of differences in how the disease shows up in women may help doctors diagnose ATTR-CM earlier in female patients.

An analysis of 14 studies of adults with ATTR-CM found that SGLTI2i use lowered the risk of mortality and heart failure hospitalization.

Eplontersen did not significantly reduce cardiovascular death or events in transthyretin amyloid cardiomyopathy (ATTR-CM).

New research links acoramidis to improved kidney function markers in people with ATTR-CM, alongside its known heart benefits.

A new review finds rare disease studies often record only age and sex, missing key demographic factors that shape patients’ care.

Novo Nordisk has received Fast Track designation from the FDA for coramitug, a humanized monoclonal antibody drug, in ATTR-CM.

New research shows that tafamidis increases natural antibody levels in patients with ATTR-CM, independent of TTR protein concentration.

Acoramidis was associated with lower mortality and fewer hospitalizations in ATTR-CM at 54 months, with greater benefit when started early.